Crossmark Global Holdings, Inc. Eli Lilly & CO Transaction History

Crossmark Global Holdings, Inc.

$5.61 Billion
Q3 2024

A detailed history of Crossmark Global Holdings, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 36,110 shares of LLY stock, worth $28.7 Million. This represents 0.57% of its overall portfolio holdings.

Number of Shares

36,110

Previous 37,103 2.68%

Holding current value

$28.7 Million

Previous $33.6 Million 4.77%

% of portfolio

0.57%

Previous 0.64%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 04, 2024	SELL	$772.14 - $960.02 $766,735 - $953,299	-993 Reduced 2.68%	36,110 $32 Million
Q2 2024 Jul 29, 2024	BUY	$724.87 - $909.04 $429,847 - $539,060	593 Added 1.62%	37,103 $33.6 Million
Q1 2024 May 13, 2024	SELL	$592.2 - $792.28 $362,426 - $484,875	-612 Reduced 1.65%	36,510 $28.4 Million
Q4 2023 Feb 13, 2024	SELL	$525.19 - $619.13 $841,354 - $991,846	-1,602 Reduced 4.14%	37,122 $21.6 Million
Q3 2023 Nov 08, 2023	SELL	$434.7 - $599.3 $160,839 - $221,740	-370 Reduced 0.95%	38,724 $22.4 Million
Q2 2023 Jul 31, 2023	BUY	$350.74 - $468.98 $210,794 - $281,856	601 Added 1.56%	39,094 $17.9 Million
Q1 2023 May 12, 2023	SELL	$310.63 - $364.82 $4.92 Million - $5.78 Million	-15,839 Reduced 29.15%	38,493 $13.2 Million
Q4 2022 Jan 19, 2023	SELL	$321.55 - $374.67 $2.13 Million - $2.48 Million	-6,620 Reduced 10.86%	54,332 $19.9 Million
Q3 2022 Nov 01, 2022	SELL	$296.48 - $337.87 $217,912 - $248,334	-735 Reduced 1.19%	60,952 $19.7 Million
Q2 2022 Jul 29, 2022	BUY	$278.73 - $327.27 $848,732 - $996,537	3,045 Added 5.19%	61,687 $20 Million
Q1 2022 May 11, 2022	SELL	$234.69 - $291.66 $60,784 - $75,539	-259 Reduced 0.44%	58,642 $16.8 Million
Q4 2021 Jan 10, 2022	SELL	$224.85 - $279.04 $19.6 Million - $24.3 Million	-87,108 Reduced 59.66%	58,901 $16.3 Million
Q3 2021 Oct 21, 2021	BUY	$221.6 - $272.71 $27.3 Million - $33.6 Million	123,128 Added 538.12%	146,009 $33.7 Million
Q3 2021 Oct 13, 2021	SELL	$221.6 - $272.71 $27.1 Million - $33.3 Million	-122,118 Reduced 84.22%	22,881 $1.09 Million
Q2 2021 Jul 21, 2021	BUY	$180.55 - $233.54 $71,317 - $92,248	395 Added 0.27%	144,999 $33.3 Million
Q1 2021 Apr 15, 2021	SELL	$164.32 - $212.72 $1.33 Million - $1.72 Million	-8,078 Reduced 5.29%	144,604 $27 Million
Q4 2020 Jan 14, 2021	BUY	$130.46 - $172.63 $9.77 Million - $12.9 Million	74,857 Added 96.19%	152,682 $25.8 Million
Q3 2020 Oct 08, 2020	SELL	$146.22 - $169.13 $42,403 - $49,047	-290 Reduced 0.37%	77,825 $11.5 Million
Q2 2020 Aug 14, 2020	BUY	$136.42 - $164.18 $214,452 - $258,090	1,572 Added 2.05%	78,115 $12.8 Million
Q1 2020 Apr 28, 2020	SELL	$119.05 - $147.35 $569,416 - $704,775	-4,783 Reduced 5.88%	76,543 $10.6 Million
Q4 2019 Feb 06, 2020	SELL	$106.92 - $132.43 $1.1 Million - $1.36 Million	-10,283 Reduced 11.22%	81,326 $10.7 Million
Q3 2019 Oct 09, 2019	SELL	$106.79 - $116.16 $314,069 - $341,626	-2,941 Reduced 3.11%	91,609 $10.2 Million
Q2 2019 Jul 09, 2019	SELL	$110.79 - $129.32 $881,777 - $1.03 Million	-7,959 Reduced 7.76%	94,550 $10.5 Million
Q1 2019 May 02, 2019	SELL	$111.31 - $131.02 $415,742 - $489,359	-3,735 Reduced 3.52%	102,509 $13.3 Million
Q4 2018 Jan 31, 2019	BUY	$105.9 - $118.64 $468,819 - $525,219	4,427 Added 4.35%	106,244 $12.3 Million
Q3 2018 Nov 08, 2018	SELL	$85.86 - $107.31 $362,500 - $453,062	-4,222 Reduced 3.98%	101,817 $10.9 Million
Q2 2018 Jul 31, 2018	SELL	$75.7 - $86.88 $355,638 - $408,162	-4,698 Reduced 4.24%	106,039 $9.05 Million
Q1 2018 Apr 16, 2018	SELL	$74.21 - $87.6 $41,409 - $48,880	-558 Reduced 0.5%	110,737 $8.57 Million
Q4 2017 Feb 05, 2018	BUY	$81.94 - $87.89 $664,697 - $712,963	8,112 Added 7.86%	111,295 $9.4 Million
Q3 2016 Oct 25, 2017	BUY	N/A	103,183	103,183 $8.83 Million

Others Institutions Holding LLY

# of Institutions

4,011

Shares Held

751M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.

Account

Crossmark Global Holdings, Inc. Eli Lilly & CO Transaction History